➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Harvard Business School
Medtronic
Baxter
McKinsey

Last Updated: January 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for C1-INH

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug C1-INH?

C1-INH is an investigational drug.

There have been 5 clinical trials for C1-INH. The most recent clinical trial was a Phase 1 trial, which was initiated on November 16th 2016.

The most common disease conditions in clinical trials are Wounds and Injuries, Reperfusion Injury, and Ischemia. The leading clinical trial sponsors are CSL Behring, Universitaire Ziekenhuizen Leuven, and Sanquin.

There are sixteen US patents protecting this investigational drug and one hundred and twenty-one international patents.

Recent Clinical Trials for C1-INH
TitleSponsorPhase
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant RecipientsCSL BehringPhase 3
C1-inhibitor in Allergic ASThma PatientsSanquinPhase 4
C1-inhibitor in Allergic ASThma PatientsZonMw: The Netherlands Organisation for Health Research and DevelopmentPhase 4

See all C1-INH clinical trials

Clinical Trial Summary for C1-INH

Top disease conditions for C1-INH
Top clinical trial sponsors for C1-INH

See all C1-INH clinical trials

US Patents for C1-INH

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
C1-INH   Start Trial Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders SHIRE VIROPHARMA INCORPORATED (Lexington, MA)   Start Trial
C1-INH   Start Trial Protein biomarkers for immune assessment and prediction of transplant rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)   Start Trial
C1-INH   Start Trial Combination therapy using immunoglobulin and C1-Inhibitor CSL BEHRING GMBH (Marburg, DE) THE GOVERNMENT OF THE UNITED STATES OF AMERICA (Rockville, MD)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Harvard Business School
Medtronic
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.